4BIO Capital-backed Ascend completed the acquisition of Contract, Manufacturing And Controls Team from Beacon Therapeutics.

4BIO Capital-backed Ascend, an end-to-end gene therapy development company, completed the acquisition of Contract, Manufacturing And Controls Team from Beacon Therapeutics, an ophthalmic gene therapy company. Financial terms were not disclosed. “The gene and cell therapy industry is evolving at speed and there remains a significant unmet need for highly sophisticated manufacturing companies that can act as partners and provide support to ensure patients get advanced therapies. This key acquisition brings Ascend its first US manufacturing site, a huge milestone for the Company. We are proud to support Ascend as it takes the next steps toward achieving its vision,” Andrew Kozlov, 4BIO Capital Managing Partner.